Want to see MDAI full AI Analyst Report?
MDAI Stock Chart & Stats
$1.58
-$0.15(-6.16%)
At close: 4:00 PM EST
$1.58
-$0.15(-6.16%)
Day’s Range― - ―
52-Week Range$1.18 - $2.97
Previous CloseN/A
Volume689.87K
Average Volume (3M)272.42K
Market Cap
$52.51M
Enterprise Value$55.88M
Total Cash (Recent Filing)$11.65M
Total Debt (Recent Filing)$9.94M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 18, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding31,823,984
10 Day Avg. Volume290,415
30 Day Avg. Volume272,420
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-6.58
Price to Sales (P/S)1.92
P/FCF Ratio-3.80
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit7.48
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$4.00Price Target Upside153.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$18.81M
Bulls Say, Bears Say
Bulls Say
FDA De Novo ClearanceRegulatory authorization is a durable structural milestone: De Novo clearance validates the DeepView clinical claim and legally enables U.S. commercialization, opening hospital/ED channels, facilitating payer conversations and creating a foundation for sustainable revenue and market access over the next months.
Commercial Leadership HireAdding an experienced CCO with device launch track record materially strengthens go‑to‑market capability. This leadership aligns incentives via equity and bonus, improving execution odds of translating FDA clearance into durable commercial adoption across burn centers and trauma networks over the medium term.
Non-dilutive Funding & Proprietary DataSubstantial BARDA support reduces near-term capital pressure and signals clinical utility. The proprietary imaging dataset creates a durable competitive advantage for AI model performance and clinical validation, raising barriers to entry and supporting sustained product differentiation and adoption.
Bears Say
Negative Shareholders' EquityPersistent equity deficit and meaningful debt weaken financial flexibility, increasing reliance on external financing. This structural capital weakness can force dilutive raises or expensive debt, constraining long‑term investment in commercialization, R&D and limiting the company’s ability to scale operations sustainably.
Sustained Cash BurnMaterial negative operating and free cash flow imply the company cannot self‑fund growth. Continued cash burn creates runway risk and may compel financing during commercialization, potentially delaying deployments and forcing tradeoffs between sales investment and R&D, which undermines execution durability.
Weak Revenue And LossesDeclining revenue and persistent operating losses signal insufficient commercial traction to date. Even with steady mid‑40% gross margins, negative EBITDA and worsening TTM revenue suggest the business model has not yet achieved sustainable unit economics, raising execution and adoption risk during rollout.
Spectral AI News
MDAI FAQ
What was Spectral AI’s price range in the past 12 months?
Spectral AI lowest stock price was $1.18 and its highest was $2.97 in the past 12 months.
What is Spectral AI’s market cap?
Spectral AI’s market cap is $52.51M.
When is Spectral AI’s upcoming earnings report date?
Spectral AI’s upcoming earnings report date is Aug 18, 2026 which is in 32 days.
How were Spectral AI’s earnings last quarter?
Spectral AI released its earnings results on May 12, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.022.
Is Spectral AI overvalued?
According to Wall Street analysts Spectral AI’s price is currently Undervalued.
Does Spectral AI pay dividends?
Spectral AI does not currently pay dividends.
What is Spectral AI’s EPS estimate?
Spectral AI’s EPS estimate is -0.16.
How many shares outstanding does Spectral AI have?
Spectral AI has 31,823,984 shares outstanding.
What happened to Spectral AI’s price movement after its last earnings report?
Spectral AI reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went down -5.116%.
Which hedge fund is a major shareholder of Spectral AI?
Currently, no hedge funds are holding shares in MDAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spectral AI Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (153.16% Upside)
$4.00 (153.16% Upside)
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.06%
12-Months-Change
Fundamentals
Return on Equity
179.24%
Trailing 12-Months
Asset Growth
-14.42%
Trailing 12-Months
Company Description
Spectral AI
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
MDAI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive progression: key clinical and regulatory milestones (successful validation study, de novo submission and response) and a substantial BARDA funding acceleration materially de-risk near-term development. Financially, liquidity improved materially (cash tripled) and operating efficiencies reduced losses. However, there are meaningful near-term headwinds and uncertainties — reduced reimbursed R&D revenue as BARDA base-phase work winds down, continued full-year loss, dependence on BARDA and FDA timing, and revenue recognition/timing risks around BARDA-subsidized device placements. On balance the call emphasized tangible progress toward commercialization and improved financial footing while acknowledging execution and timing risks.View all MDAI earnings summariesMDAI Stock 12 Month Forecast
Average Price Target
$4.00
▲(153.16% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
9.99% Insiders
3.48% Mutual Funds
4.71% Other Institutional Investors
78.45% Public Companies and
Individual Investors